Novadip is transforming the lives of patients using its unique tissue regeneration technology platform.
The company’s highly experienced management team has a deep knowledge of science, regulation and development pathways as well a proven track record in significant fundraising for regenerative medicine companies.
Founded in 2013, based on the scientific discoveries of Dr. Denis Dufrane , Novadip is a spin-off company from the University of Louvain (UCL) and St. Luc University Hospital. The creation of Novadip was supported by the Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II.
Using our proprietary scaffold-free, 3-dimensional technology platform for tissue regeneration to develop multiple product classes, Novadip’s mission is to provide innovative solutions for patients with limited or no effective treatment options.
2007 Reflection begins on the best stem cells for large bone defect reconstruction.
2008 Innovative 3-dimensional osteogenic structure is developed in the tissue bank at Cliniques universitaires Saint-Luc.
2009 Bone reconstruction is demonstrated in pre-clinical studies.
2010 Patent WO2010/139792 is granted for a “multi-dimensional biomaterial” and its production method. (Inventors: D. Dufrane & C. Delloye).
2010 First clinical application of the biological dressing for skin reconstruction in a chronic wound after radionecrosis is demonstrated.
2010 First clinical cases with bone regeneration therapy, in the hospital exemption setting, as a salvage therapy for bone tumour and non-union indications, show positive safety and efficacy outcomes.
2011 The selection of adipose stem cells as the best candidate for bone reconstruction is published in Biomaterials Journal.
2012 New clinical cases with for lumbar spine and degenerative disc disease indications also demonstrate positive safety and efficacy outcomes.
2013 Preclinical results are published in Biomaterials, a leading international journal covering the science and clinical application of biomaterials.
2013 Novadip Biosciences is set-up, with a capital increase of EUR 500.000.
2013 Novadip receives grants of EUR 550.000 in non-dilutive funding from the Walloon Region.
2015 Novadip closes a EUR 28 million Series A financing round with US and Belgian investors.
2015 Novadip is granted additional EUR 4.5 million in non-dilutive funding by the Walloon Region.
2015 The development of the concept of the biological dressing for skin reconstruction is published in the American Journal of Plastic Surgery.
2015 The clinical results of skin regeneration therapy regarding safety and efficacy, are published in: Human Adipose-Derived Mesenchymal Stem Cells in Cell Therapy: Safety and Feasibility in Different «Hospital Exemption» Clinical Applications. Vériter S, André W, Aouassar N, Poirel HA, Lafosse A, Docquier PL, Dufrane D. PLoS One. 2015 Oct 20;10(10):e0139566
2016 Novadip develops and publishes a tool to discriminate adipose stem cells to fibroblasts. Lafosse A, Dufrane D. (2016) A simple method to determine the purity human adipose-derived stem cells-based cell therapies. Stem Cell Trans Med. 2016 (in press)
2017 Novadip initiates first clinical trial testing first product candidate for bone regeneration in patients requiring single-level spinal fusion
2018 Novadip initiates first clinical trial testing second product candidate for bone regeneration in patients with large bone non-union fractures
2018 Novadip moves into its new facility with in-house GMP Class A/B cleanrooms for production of clinical batches